Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 8c
August 4, 2016 7:36 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.84), $0.08 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $59 thousand versus the consensus estimate of $40 thousand.
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
... More